The usage for treating obesity is subcutaneous injection once a week
Someone stopping these medications doesnt have the same control over their obesity, and their weight can increase. What to expect Nearly 12% of Americans about one in eight have used GLP-1 drugs for weight loss, according to a 2025 report from RAND, a nonprofit research organization
Because the current evidence base is still driven largely by case reports rather than large controlled studies, clinicians generally evaluate renal complications in the full context of dose, product type, co-exposures, dehydration, muscle breakdown, and other signs of systemic toxicity
This potential risk of thyroid cancer is a huge deal for patients for two important reasons: The first
In product liability cases specifically, we previously secured individual settlements of $4 million and $3.15 million for clients in Lake County, Illinois
doi: 10.1210/endocr/bqae155 [DOI] [PMC free article] [PubMed] [Google Scholar] 134.Verdich C, Flint A, Gutzwiller JP, et al